Extracellular Vesicle‐Based Approaches in Acute Myeloid Leukemia: Therapeutic Potential and Translational Challenges
European Journal of Haematology · 2026-12 · 117 (6) · 1500-1517
DOI: 10.1111/ejh.70308 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift European Journal of Haematology, online erschienen am 31.08.2026. Verfasst von Ghaleb Oriquat und 8 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Allied Medical Sciences, Hourani Center for Applied Scientific Research, Al-Ahliyya Amman University, Amman, Jordan. Hauptthemen laut MEDLINE: Extracellular Vesicles, Leukemia, Myeloid, Acute. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 78 Literaturangaben.
Abstract (Originalsprache)
Acute myeloid leukemia (AML) is an aggressive and heterogeneous hematological malignancy in which treatment resistance and relapse remain major causes of mortality. Extracellular vesicles (EVs) contribute to AML progression by mediating communication among leukemic blasts, leukemia stem cells, hematopoietic stem and progenitor cells, stromal and endothelial cells, and immune‐cell populations. Experimental studies indicate that AML‐associated EVs can remodel the bone marrow niche, suppress normal hematopoiesis, impair antileukemic immune responses, promote leukemic‐cell survival, and facilitate drug resistance. Their surface markers and molecular cargo, including proteins, miRNAs, mRNAs, DNA, lipids, and metabolites, have also prompted investigation into their use as liquid‐biopsy biomarkers. Candidate EV‐based markers include particle abundance, blast‐associated antigens, TGF‐β1, FLT3‐ITD and NPM1 alterations, and several circulating miRNAs. However, most biomarker studies remain small, heterogeneous, and insufficiently compared with established measurable residual disease assays. Therapeutic strategies involving inhibition of EV release or uptake, EV‐based immunotherapy, and engineered EVs for drug or RNA delivery are also being explored, but current evidence is predominantly preclinical. Clinical translation is further limited by inconsistent terminology, variable isolation and characterization methods, contamination by non‐vesicular particles, and a lack of prospective multicenter validation. This review summarizes the biological roles, biomarker potential, therapeutic applications, and methodological challenges of EVs in AML and highlights the priorities required for their future clinical development.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Faculty of Allied Medical Sciences, Hourani Center for Applied Scientific Research, Al-Ahliyya Amman University, Amman, Jordan.
- College of Pharmacy, The Islamic University, Najaf, Iraq.
- Department of Medical Analysis, Medical Laboratory Technique College, The Islamic University of Al Diwaniyah, Al Diwaniyah, Iraq.
- Department of Medicinal Chemistry, Al-Turath University, Baghdad, Iraq.
- Department of Biotechnology and Genetics, School of Sciences, JAIN (Deemed to be University), Bangalore, Karnataka, India.
- Department of General Medicine, IMS and SUM Hospital, Siksha 'O' Anusandhan, Bhubaneswar, Odisha, India.
Zitieren
APA
Oriquat, G., Al-Hasnaawei, S., Mousa, H. M., Malathi, H., Sahoo, S., Prathiba, S., Singh, G., Sinha, A., & Abdalla, R. (2026). Extracellular Vesicle‐Based Approaches in Acute Myeloid Leukemia: Therapeutic Potential and Translational Challenges. European Journal of Haematology, 117(6), 1500-1517. https://doi.org/10.1111/ejh.70308
Vancouver
Oriquat G, Al-Hasnaawei S, Mousa HM, Malathi H, Sahoo S, Prathiba S, et al. Extracellular Vesicle‐Based Approaches in Acute Myeloid Leukemia: Therapeutic Potential and Translational Challenges. European Journal of Haematology. 2026;117(6):1500-1517. doi:10.1111/ejh.70308
BibTeX
@article{Oriquat2026,
author = {Oriquat, Ghaleb and Al-Hasnaawei, Shaker and Mousa, Hayjaa Mohaisen and Malathi, H and Sahoo, Samir and Prathiba, S and Singh, Gurjant and Sinha, Aashna and Abdalla, Rufaida},
title = {Extracellular Vesicle‐Based Approaches in Acute Myeloid Leukemia: Therapeutic Potential and Translational Challenges},
journal = {European Journal of Haematology},
year = {2026},
volume = {117},
number = {6},
pages = {1500--1517},
doi = {10.1111/ejh.70308}
}
EUVIMED